PTC Therapeutics, Inc. PTCT
Set alert
68.31 USD +7.43 +12.21%
As of Nov 3, 2:18 PM ET
63.16 Day range 68.72
58.80 52-week range 90.87
- YTD
- -10.07%
- 1 year
- +0.57%
- Open
- 63.69
- Prev close
- 60.88
- Mkt cap
- 5.71B
- Vol
- 1.45M
- Avg vol
- 1.06M
- EPS
- -1.47
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 63.16
- High
- 68.72
- Forward P/E
- 25.05
- Beta
- 0.51
- Short ratio
- 6.38
- Inst. own
- 122.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 18, 2027
- 50-d avg
- 65.36
- 200-d avg
- 70.67
- 1y target
- 100.40
5D chart
Events in this range
- Oct 29, 2026Earnings: -0.62; estimate 0.1434; surprise -532.36%
- Oct 30, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 30, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 30, 2026Rating: TD Cowen · Buy → Buy
- Nov 2, 2026Rating: Citigroup · Buy → Buy
Signals (105)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 3, 11:20 AM | 2 hours ago |
| MACD: Sell Signal | Nov 3, 11:10 AM | 3 hours ago |
| SMA: Bullish | Nov 3, 9:30 AM | 4 hours ago |
| SMA: Bullish | Nov 3, 9:30 AM | 4 hours ago |
| MACD: Buy Signal | Nov 3, 9:30 AM | 4 hours ago |
| RSI: Overbought | Nov 3, 9:30 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 3:55 PM | 22 hours ago |
| MACD: Sell Signal | Nov 2, 3:55 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 3:50 PM | 22 hours ago |
| MACD: Buy Signal | Nov 2, 3:50 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 3:45 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 3:35 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 3:25 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 3:20 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 3:05 PM | 23 hours ago |
| SMA: Bearish | Nov 2, 2:30 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 2:00 PM | 1 day ago |
| SMA: Bearish | Nov 2, 1:50 PM | 1 day ago |
| MACD: Sell Signal | Nov 2, 1:50 PM | 1 day ago |
Newest 20 of 105.
Financial health
Altman Z-Score
0.75 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E 8.9×
FY 2016 5y median -4.9× FY 2025
P/S 3.5×
FY 2016 5y median 3.9× FY 2025
P/B -29.4×
FY 2016 5y median -3.2× FY 2025
P/FCF 14.7×
FY 2016 5y median -7.4× FY 2025
EV/EBITDA 8.7×
FY 2016 5y median -10.7× FY 2025
EV/Sales 4.5×
FY 2016 5y median 5.6× FY 2025
FCF Yield 6.8%
FY 2016 5y median -12.0% FY 2025
Profitability
Gross Margin 95.9%
FY 2016 5y median 93.6% FY 2025
Operating Margin 49.5%
FY 2016 5y median -46.9% FY 2025
Net Margin 39.4%
FY 2016 5y median -66.8% FY 2025
ROE -332.5%
FY 2016 5y median 33.1% FY 2025
ROIC 33.4%
FY 2016 5y median -22.7% FY 2025
ROA 23.5%
FY 2016 5y median -27.0% FY 2025
Growth (YoY)
Revenue 114.5%
FY 2016 FY 2025
Operating Income 383.1%
FY 2016 FY 2025
EPS (diluted) 264.5%
FY 2016 FY 2025
Free Cash Flow 326.0%
FY 2016 FY 2025
Financial Health
Current Ratio 2.3×
FY 2016 5y median 2.0× FY 2025
Quick Ratio 2.3×
FY 2016 5y median 2.0× FY 2025
Debt / Equity -13.2×
FY 2016 5y median -2.7× FY 2025
Net Debt / EBITDA 1.9×
FY 2016 5y median -3.2× FY 2025
Interest Coverage 5.6×
FY 2016 5y median -3.4× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
